Scholarlink

Background <p>Major depressive disorder (MDD) is a common severe mental disorder with enormous socioeconomic costs for the patient and society alike. Current pharmacological and psychotherapeutic treatments are ineffective in a substantial fraction of patients and can be accompanied by unwanted side effects.</p> Methods <p>Using a novel non-invasive brain stimulation method to specifically target and modulate dysfunctional brain oscillations with high spatial and temporal precision this study will investigate the efficacy of EEG-triggered transcranial magnetic stimulation (TMS) to alleviate depressive symptoms in 28 patients with MDD in a 1:1-randomized, double blind, standard treatment-controlled pilot trial. In the experimental condition, stimulation will be brain oscillation-synchronized based on the EEG-extracted endogenous theta oscillation over left dorsomedial prefrontal cortex (DMPFC). The control condition will consist of standard TMS therapy following an FDA-approved intermittent theta-burst stimulation (iTBS) protocol over left dorsolateral prefrontal cortex (DLPFC). The treatment will be performed over four consecutive weeks (20 sessions) and the primary outcome will be the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) after the last versus before the first treatment session.</p> Discussion <p>The aim of the study is to gain exploratory evidence for the feasibility and efficacy of EEG-synchronized TBS of left DMPFC compared to a standard FDA-approved treatment (iTBS of left DLPFC) in a double-blind randomized parallel-design pilot clinical trial. Positive results will pave the way for a larger RCT to prove the superiority of personalized, brain oscillation-synchronized non-invasive brain stimulation therapies as novel, effective and well-tolerated treatment in MDD.</p> Trial registration <p><i>Trial Registration</i>: NCT06345651, date of registration: 2024-01-08, <a href="https://clinicaltrials.gov/study/NCT06345651">https://clinicaltrials.gov/study/NCT06345651</a>The trial is conducted in accord with protocol version number 2022-09, Version 3. Recruitment started in January 2024, and recruitment is ongoing. The recruitment phase is projected to conclude by December 2026.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Brain oscillation-synchronized stimulation for major depression: a randomized controlled trial comparing EEG-triggered repetitive TMS with standard iTBS (Acronym: BOSSFRONT2)

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月21日

查看全文
  • Anne Lieb,
  • Brigitte Zrenner,
  • Julia Becker-Sadzio,
  • Pedro Caldana Gordon,
  • Gábor Kozák,
  • Christoph Zrenner,
  • Peter Martus,
  • Ulf Ziemann,
  • Andreas Fallgatter

摘要

Background

Major depressive disorder (MDD) is a common severe mental disorder with enormous socioeconomic costs for the patient and society alike. Current pharmacological and psychotherapeutic treatments are ineffective in a substantial fraction of patients and can be accompanied by unwanted side effects.

Methods

Using a novel non-invasive brain stimulation method to specifically target and modulate dysfunctional brain oscillations with high spatial and temporal precision this study will investigate the efficacy of EEG-triggered transcranial magnetic stimulation (TMS) to alleviate depressive symptoms in 28 patients with MDD in a 1:1-randomized, double blind, standard treatment-controlled pilot trial. In the experimental condition, stimulation will be brain oscillation-synchronized based on the EEG-extracted endogenous theta oscillation over left dorsomedial prefrontal cortex (DMPFC). The control condition will consist of standard TMS therapy following an FDA-approved intermittent theta-burst stimulation (iTBS) protocol over left dorsolateral prefrontal cortex (DLPFC). The treatment will be performed over four consecutive weeks (20 sessions) and the primary outcome will be the change in the Montgomery-Åsberg Depression Rating Scale (MADRS) after the last versus before the first treatment session.

Discussion

The aim of the study is to gain exploratory evidence for the feasibility and efficacy of EEG-synchronized TBS of left DMPFC compared to a standard FDA-approved treatment (iTBS of left DLPFC) in a double-blind randomized parallel-design pilot clinical trial. Positive results will pave the way for a larger RCT to prove the superiority of personalized, brain oscillation-synchronized non-invasive brain stimulation therapies as novel, effective and well-tolerated treatment in MDD.

Trial registration

Trial Registration: NCT06345651, date of registration: 2024-01-08, https://clinicaltrials.gov/study/NCT06345651The trial is conducted in accord with protocol version number 2022-09, Version 3. Recruitment started in January 2024, and recruitment is ongoing. The recruitment phase is projected to conclude by December 2026.